KYMR

Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?

KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events:  Wells Fargo 21st Annual Healthcare Conference in Boston, MA on September 9 at 8:00 AM ET; Citi 2026 Biopharma Back to School Summit in New York, NY on September 10 at 11:20 AM ET; H.C.

Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data expected in late 2027 WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will present two posters featuring previously reported data from the BroADen Phase 1b trial evaluating KT-621, its first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD).

Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.

Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript

Kymera Therapeutics NASDAQ: KYMR said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by the end of 2026 and potentially begin Phase 3 development around mid-2027.

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago.

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 4Q26 KT-485 (IRAK4) Phase 1 trial commenced in healthy volunteers and HS patients by partner Sanofi Well-capitalized with $1.5 billion in cash as of June 30, 2026, and runway into 2029 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass.

WATERTOWN, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report second quarter 2026 financial results on August 5, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.